Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
Executive Summary
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25